| Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
0.100 | GeneticVariation | BEFREE | Then, two-way analysis of covariance (ANCOVA) was applied to investigate main effects and interactions of PD and DRD3 Ser9Gly polymorphism on the brain function via amplitude of low-frequency fluctuations (ALFF) approach. | 31143436 | 2019 |
||||
|
0.100 | GeneticVariation | BEFREE | We found that behavioral addictions in PD are associated with an early onset of the disease, the rs6280 DRD3 SNV and the type of dopamine agonist. | 29361389 | 2018 |
||||
|
0.100 | GeneticVariation | BEFREE | Twenty-eight patients with PD were genotyped for known functional polymorphisms in DRD2 (rs6277 and rs1800497) and DRD3 (rs6280) receptors. | 29856137 | 2018 |
||||
|
0.100 | GeneticVariation | BEFREE | Association of the DRD2 CA<sub>n</sub>-STR and DRD3 Ser9Gly polymorphisms with Parkinson's disease and response to dopamine agonists. | 27817855 | 2017 |
||||
|
0.100 | GeneticVariation | BEFREE | Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients. | 27325396 | 2016 |
||||
|
0.100 | GeneticVariation | BEFREE | The DRD3 (rs6280) polymorphism, but not DRD2 (Taq1A) or GRIN2B, influences younger PD age of onset in the US Caucasian population. | 26627941 | 2016 |
||||
|
0.100 | GeneticVariation | BEFREE | The presence of diphasic dyskinesia (DDSK) was exclusively associated with the DRD3 p.S9G variant after adjusting for gender, age at PD onset, Hoehn & Yahr stage, and duration of levodopa treatment. | 20945430 | 2011 |
||||
|
0.100 | GeneticVariation | BEFREE | Among white Hispanics who carried two alleles, the Ser9Gly DRD3 (rs6280) polymorphism was associated with a decreased risk of PD (OR=0.4, 95% CI 0.2-0.8). | 21663922 | 2011 |
||||
|
0.100 | GeneticVariation | BEFREE | We did not identify any effect of DRD3 Ser9Gly on tremor in PD, even when regarding various symptom combinations to avoid missing a weak effect on the phenotype. | 20434388 | 2010 |
||||
|
0.100 | GeneticVariation | BEFREE | As recent observations indicate the dopamine D(3) receptor (DRD3) to modulate both therapeutic action of levodopa and dyskinesia, we reappraised the impact of the DRD3 Ser9Gly polymorphism on development of motor complications in a large scale association study based on the gene bank of the German Competence Network on Parkinson's disease. | 19353703 | 2009 |
||||
|
0.100 | GeneticVariation | BEFREE | Variants of DRD3 p.S9G and GRIN2B c.366C>G may be associated with the appearance of ICRB in PD. | 19562769 | 2009 |
||||
|
0.100 | GeneticVariation | BEFREE | We aim to evaluate the role of the Ser9Gly variant in DRD3 and Ala265Gly in HS1BP3 in PD development. | 19524641 | 2009 |
||||
|
0.100 | GeneticVariation | BEFREE | DRD3 Ser9Gly polymorphisms are significantly associated with the therapeutic efficacy of pramipexole in Chinese patients with PD. | 19396436 | 2009 |